p63 and FGFR: when development meets proliferation.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. 2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology.Journal of oncology · 2021
   Review
2. Expression of the FGFR2c mesenchymal splicing variant in human keratinocytes inhibits differentiation and promotes invasion.Molecular carcinogenesis · 2018
   Article
3. Cellular and Molecular Mechanisms of Palatogenesis.Current topics in developmental biology · 2015
   Review
4. miR-203 regulates progenitor cell proliferation during adult zebrafish retina regeneration.Developmental biology · 2014
   Article

Corrections and comments

• Comment on
  Mutant p63 causes defective expansion of ectodermal progenitor cells and impaired FGF signalling in AEC syndrome.2012

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as